1970s
The Nobel Discovery
Learning the Brain's Language
Key moment
1977 Nobel Prize for discovering releasing hormones
For decades, scientists knew the pituitary gland released hormones that controlled growth, reproduction, and stress response. But what controlled the pituitary? The answer turned out to be the hypothalamus — a small region at the base of the brain.
In 1977, Roger Guillemin and Andrew Schally shared the Nobel Prize for discovering 'releasing hormones' — small peptides from the hypothalamus that told the pituitary what to make. It was like finding the control panel for the body's hormone factory.
The race was on to identify every releasing hormone. Growth hormone was controlled by the pituitary, so there had to be a Growth Hormone Releasing Hormone. Finding it would open doors to treating children who couldn't grow.
1982-1990
Finding GHRH
The Sequence Revealed
Key moment
First 29 amino acids found to have full activity
In 1982, two research teams — one led by Wylie Vale at the Salk Institute, another by Guillemin himself — simultaneously identified GHRH. The full hormone was 44 amino acids long. But Vale's team made a crucial discovery: only the first 29 amino acids were needed for full activity.
This 29-amino-acid fragment became sermorelin. It was easier to manufacture than the full hormone, and it worked just as well. Pharmaceutical company EMD Serono began developing it for clinical use.
The first application was diagnostic. Doctors could inject sermorelin and measure the pituitary's response. If growth hormone levels rose normally, the pituitary was working — the problem was elsewhere. If levels stayed flat, the pituitary itself was defective.
1990-1997
FDA Approval
From Diagnosis to Treatment
Key moment
FDA approved for diagnosis (1990) and treatment (1997)
In December 1990, the FDA approved Geref for diagnostic use — testing pituitary function in children with growth problems. Doctors finally had a reliable way to find out why a child wasn't growing.
But sermorelin could do more than diagnose. In 1997, the FDA expanded the approval to include treatment. Children with growth hormone deficiency who had functioning pituitary glands could now receive sermorelin instead of growth hormone injections.
The appeal was philosophical as much as medical. Injecting growth hormone overrides your body's control systems. Sermorelin just sends a signal, letting your pituitary decide how much hormone to release and when. For some doctors and parents, this felt more natural, more respectful of the body's wisdom.
2008
The Withdrawal
Business Beats Science
Key moment
Withdrawn for commercial reasons, not safety concerns
In 2008, EMD Serono withdrew Geref from the market. Not because it didn't work. Not because it wasn't safe. Simply because it wasn't profitable enough.
The market for childhood growth hormone deficiency was small. Recombinant growth hormone — injected directly — dominated the market with better-known brands and established protocols. Sermorelin was an also-ran that never achieved the sales numbers to justify continued production.
But here's what the withdrawal didn't mean: it didn't mean sermorelin was banned, dangerous, or discredited. The FDA specifically noted that the withdrawal was 'not for reasons of safety or effectiveness.' This would become important for what happened next.
2010-Present
The Compounding Renaissance
A Second Life
Key moment
Compounding pharmacies keep sermorelin available
With the branded product gone, compounding pharmacies stepped in. These specialized pharmacies can legally produce medications that are not commercially available, including sermorelin.
Anti-aging and wellness clinics began prescribing compounded sermorelin to adults. The pitch: stimulate your body's natural growth hormone production to combat aging. Improve sleep. Build muscle. Burn fat. Increase energy. All by asking your pituitary to work a little harder.
The science on adult use is mixed. Some studies show benefits, others don't. But sermorelin has developed a devoted following among patients who report improved quality of life. Meanwhile, researchers continue studying GHRH-based peptides, with newer versions like tesamorelin and CJC-1295 building on sermorelin's foundation.
Peptide history · 1980
Sermorelin Acetate (Geref)
The Natural Approach — Telling Your Body to Make Its Own Growth Hormone
Instead of injecting growth hormone directly, what if you could just ask your body to make more? Sermorelin does exactly that — it's the first 29 amino acids of the hormone that tells your pituitary gland to release growth hormone naturally.
Approved then withdrawn 2008
Shortest active GHRH fragment
Daltons
Original prescription form
Short-acting
Available through compounding pharmacies
Dr. Roger Guillemin
The Nobel Laureate · Salk Institute
Won the 1977 Nobel Prize for discovering that the brain controls hormone release through 'releasing factors.' His work on hypothalamic hormones laid the foundation for all GHRH research.
The brain speaks to the body through chemical messengers. Once we understood this language, we could begin to write our own messages.
Dr. Wylie Vale
The GHRH Pioneer · Salk Institute
Identified and characterized Growth Hormone Releasing Hormone (GHRH) in 1982, determining its complete amino acid sequence and proving which fragment was necessary for activity.
We found that just the first 29 amino acids — out of 44 — were enough to trigger full growth hormone release. That became sermorelin.
EMD Serono
The Developers · Pharmaceutical Company
Brought sermorelin to market as Geref in 1990 for diagnostic testing and in 1997 for treating growth hormone deficiency in children. Made the peptide available for clinical use.
A gentler approach to growth hormone replacement — working with the body rather than overriding it.
10 milestones, 1977 – 2024.
- 1977Nobel Prize awarded for discovering releasing hormones
- 1982GHRH identified and sequenced
- 1984Sermorelin (first 29 amino acids) shown to have full activity
- 1990FDA approves Geref for diagnostic use
- 1997FDA expands approval for treating GH deficiency
- 2008EMD Serono withdraws Geref from market
- 2013FDA confirms withdrawal not due to safety concerns
- 2015Compounded sermorelin becomes widely available
- 2020Anti-aging clinics adopt sermorelin for adults
- 2024Research continues on next-generation GHRH peptides
Your pituitary gland is like a factory that makes growth hormone. Sermorelin is the 'make more' signal — it doesn't add growth hormone from outside, it just tells your own factory to increase production. This means your body keeps control of how much is released and when.
Molecular structure
- Amino Acids
- 29
- Molecular Weight
- 3,358 Da
- Formula
- C149H246N44O42S
- Half-life
- 10-20 minutes
- Type
- GHRH fragment (1-29)
Growth Hormone Response
GH levels after sermorelin injection over time
- normal
- treated
- deficient
Point at the chart to read each line.
Show the figures
| age | normal | treated | deficient |
|---|---|---|---|
| 0 | 2 | 2 | 2 |
| 15 | 2 | 12 | 2 |
| 30 | 2 | 25 | 2 |
| 45 | 2 | 20 | 2 |
| 60 | 2 | 14 | 2 |
| 90 | 2 | 8 | 2 |
| 120 | 2 | 4 | 2 |
Benefits of Natural GH Stimulation
Reported improvements with sermorelin therapy
- direct
- indirect
Show the figures
| direct | effect | indirect |
|---|---|---|
| 95 | Increases Natural GH Release | 10 |
| 75 | Improves Sleep Quality | 35 |
| 70 | Supports Muscle Growth | 40 |
| 65 | Enhances Fat Burning | 45 |
| 60 | Boosts Energy Levels | 50 |
The cascade effect
- 01SignalSermorelin travels through your bloodstream to the pituitary gland at the base of your brain, where growth hormone is made.
- 02ResponseReceptors on pituitary cells recognize sermorelin and trigger the release of stored growth hormone — like pressing the 'go' button on the factory.
- 03Natural RhythmYour body responds with a pulse of growth hormone, but maintains its natural feedback controls. You get more GH, but your body still decides exactly how much.
Shortest fully active GHRH fragment
For diagnostic testing
Through compounding pharmacies
Short-acting peptide
Real stories, real lives
David Thompson
Adult Patient, Age 58
My doctor said my growth hormone levels were low for my age. Instead of injecting GH directly, we tried sermorelin. Within a few months, my energy improved, I was sleeping better, and I was making progress in the gym again. I like that it's just asking my body to do what it should be doing anyway.
Dr. Amanda Foster
Anti-Aging Medicine Physician
For some patients, I prefer sermorelin over direct growth hormone. It preserves the body's feedback mechanisms. The pituitary still controls the timing and amount of release. It's a gentler approach that respects the body's natural rhythms.
The future of Sermorelin
- Modified GHRH PeptidesAvailable
CJC-1295 and tesamorelin offer longer-lasting effects
- Combination TherapiesCurrent Practice
Often combined with GHRP-6 or ipamorelin for synergistic effects
- Oral FormulationsResearch Phase
Exploring ways to deliver GHRH peptides without injection
- Targeted DeliveryEarly Research
Nanoparticle systems for more efficient pituitary targeting
Be inspired
The story of Sermorelin is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.